Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Psoriasis Vulgaris

NCT01916629 NA COMPLETED Results posted

Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the safety and efficacy of Photocil in the treatment of psoriasis

Details

Lead sponsor	Applied Biology, Inc.
Phase	NA
Status	COMPLETED
Enrolment	12
Start date	2013-08
Completion	2014-12

Conditions

• Psoriasis

Interventions

• Photocil for Psoriasis
• Placebo - Sunscreen (SPF 2)

Primary outcomes

• Percent Lesion Clearance — 90 days

Countries

United States